These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 568888)

  • 1. Characteristics of the chemotactic response of neoplastic cells to a factor derived from the fifth component of complement.
    Orr W; Varani J; Ward PA
    Am J Pathol; 1978 Nov; 93(2):405-22. PubMed ID: 568888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digestion of the fifth component of complement by leukocyte enzymes. Sequential generation of chemotactic activities for leukocytes and for tumor cells.
    Orr FW; Varani J; Kreutzer DL; Senior RM; Ward PA
    Am J Pathol; 1979 Jan; 94(1):75-83. PubMed ID: 569981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further studies on the C5-derived chemotactic factor for tumor cells.
    Romualdez AG; Ward PA
    Prog Clin Biol Res; 1976; 9():65-71. PubMed ID: 193134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial characterization of a bone-derived chemotactic factor for tumor cells.
    Orr FW; Varani J; Gondek MD; Ward PA; Mundy GR
    Am J Pathol; 1980 Apr; 99(1):43-52. PubMed ID: 7361862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of a complement-derived chemotactic factor for tumor cells in human inflammatory and neoplastic effusions.
    Orr FW; Delikatny EJ; Mokashi S; Krepart GV; Stiver HG
    Am J Pathol; 1983 Jan; 110(1):41-7. PubMed ID: 6185003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between the C5 peptides chemotactic for leukocytes and tumor cells.
    Romualdez AG; Ward PA; Torikata T
    J Immunol; 1976 Nov; 117(5 Pt.2):1762-6. PubMed ID: 62790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a complement-derived chemotactic factor for tumor cells in experimentally induced peritoneal exudates and its effect on the local metastasis of circulating tumor cells.
    Orr FW; Mokashi S; Delikatny J
    Am J Pathol; 1982 Jul; 108(1):112-8. PubMed ID: 7091299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism for the inflammatory response in primate lungs. Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes.
    Kazmierowski JA; Gallin JI; Reynolds HY
    J Clin Invest; 1977 Feb; 59(2):273-81. PubMed ID: 401834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of passage, growth phase, and heterogeneity of a tumor cell population on tumor cell chemotaxis.
    Oda D; Orr FW
    Invasion Metastasis; 1984; 4(4):189-97. PubMed ID: 6533092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotactic factor for tumor cells derived from the C5a fragment of complement component C5.
    Orr W; Phan SH; Varani J; Ward PA; Kreutzer DL; Webster RO; Henson PM
    Proc Natl Acad Sci U S A; 1979 Apr; 76(4):1986-9. PubMed ID: 287038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a novel C5 inhibitor (K-76 COONa) on tumor cell chemotaxis.
    Bumpers HL; Baum J
    J Lab Clin Med; 1983 Sep; 102(3):421-7. PubMed ID: 6886523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Group B streptococci inhibit the chemotactic activity of the fifth component of complement.
    Hill HR; Bohnsack JF; Morris EZ; Augustine NH; Parker CJ; Cleary PP; Wu JT
    J Immunol; 1988 Nov; 141(10):3551-6. PubMed ID: 3053900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a neutrophil chemotactic agent by spermatozoa: role of complement and regulation by seminal plasma factors.
    Clark RA; Klebanoff SJ
    J Immunol; 1976 Oct; 117(4):1378-86. PubMed ID: 977954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.
    Perez HD; Lipton M; Goldstein IM
    J Clin Invest; 1978 Jul; 62(1):29-38. PubMed ID: 659635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1).
    Yoshimura T; Matsushima K; Oppenheim JJ; Leonard EJ
    J Immunol; 1987 Aug; 139(3):788-93. PubMed ID: 3298433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotactic activity generated in human serum from the fifth component of complement by hydrogen peroxide.
    Shingu M; Nobunaga M
    Am J Pathol; 1984 Nov; 117(2):201-6. PubMed ID: 6388344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antileukotactic properties of tumor cells.
    Brozna JP; Ward PA
    J Clin Invest; 1975 Sep; 56(3):616-23. PubMed ID: 239965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation.
    Muhlfelder TW; Niemetz J; Kreutzer D; Beebe D; Ward PA; Rosenfeld SI
    J Clin Invest; 1979 Jan; 63(1):147-50. PubMed ID: 762243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A unique complement derived chemotactic factor for tumor cells.
    Romualdez AG; Ward PA
    Proc Natl Acad Sci U S A; 1975 Oct; 72(10):4128-32. PubMed ID: 172896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotaxis of radiolabeled equine neutrophils.
    Camp CJ; Leid RW
    Am J Vet Res; 1982 Mar; 43(3):397-401. PubMed ID: 7073055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.